4-Borono-L-phenylalanine

CAS No. 76410-58-7

4-Borono-L-phenylalanine( —— )

Catalog No. M37069 CAS No. 76410-58-7

4-Borono-L-phenylalanine has antitumor activity and may be used in clinical trials of boron neutron capture therapy for the treatment of melanoma and glioblastoma multiforme.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG 26 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    4-Borono-L-phenylalanine
  • Note
    Research use only, not for human use.
  • Brief Description
    4-Borono-L-phenylalanine has antitumor activity and may be used in clinical trials of boron neutron capture therapy for the treatment of melanoma and glioblastoma multiforme.
  • Description
    (S)-2-Amino-3-(4-boronophenyl)propanoic acid is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    76410-58-7
  • Formula Weight
    209.01
  • Molecular Formula
    C9H12BNO4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    N[C@@H](Cc1ccc(cc1)B(O)O)C(O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • (R)-Apremilast

    (R)-Apremilast is the enantiomer of Apremilast and one of the isoindoline derivatives.

  • SAFit2

    SAFit2 is a highly potent and selective inhibitor of fk506 binding protein 51 (FKBP51) with a Ki value of 6 nM. SAFit2 can enhance the binding of AKT2-AS160 and participate in the downstream response of glucocorticoid release in vivo.

  • 5-(5-methyl-1H-1,2,4...

    5-(5-methyl-1H-1,2,4-triazol-3-yl)-3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazole can be used in the synthesis of heterocyclic compounds to inhibit HIF pathway activity.